Studies on lymphocyte sensitization to encephalitogenic protein in tumor patients.
The specific lymphocyte sensitization of patients with malignant diseases against a basic protein, isolated from human brain, was studied by the lymphocyte migration inhibition technique. A sensitization of lymphocytes of cancer patients against this encephalitogenic factor (EF) was first reported by FIELD and CASPARY in 1970. Their test system was the Macrophage-Electrophoretic-Mobility-Test (MEMT). In 17 out of 18 patients with malignant disease we found a specific inhibition or enhancement of the migration area of lymphocytes more than 15%.
D002283:Carcinoma, Bronchogenic / Q000276:immunology; D002464:Cell Migration Inhibition; D006801:Humans; D007414:Intestinal Neoplasms / Q000276:immunology; D008175:Lung Neoplasms / Q000276:immunology; D008213:Lymphocyte Activation; D008223:Lymphoma / Q000276:immunology; D008264:Macrophages / Q000276:immunology; D008297:Male; D008545:Melanoma / Q000276:immunology; D004676:Myelin Basic Protein / Q000276:immunology*; D009369:Neoplasms / Q000175:diagnosis / Q000276:immunology*; D013274:Stomach Neoplasms / Q000276:immunology
D004676:Myelin Basic Protein